Related Experiment Videos
Polymorphism of doxazosin mesylate.
Young-Taek Sohn1, Yoon-Hee Lee
1Young-Taek Sohn, College of Pharmacy, Duksung Women's University, 419 Ssangmun-Dong, Dobong-Gu, 132-714 Seoul, Korea. ytsohn@duksung.ac.kr
Archives of Pharmacal Research
|July 27, 2005
Summary
Nine polymorphic forms of doxazosin mesylate were identified. These crystalline structures of doxazosin mesylate remained stable under various humidity conditions, indicating consistent drug properties.
Area of Science:
- Pharmaceutical Sciences
- Solid-State Chemistry
Background:
- Doxazosin mesylate is an alpha-adrenergic blocker used to treat hypertension and benign prostatic hyperplasia.
- Understanding the polymorphic forms of active pharmaceutical ingredients (APIs) is crucial for drug formulation and bioavailability.
Purpose of the Study:
- To identify and characterize novel polymorphic modifications of doxazosin mesylate.
- To assess the stability of doxazosin mesylate polymorphs under varying humidity conditions.
Main Methods:
- Recrystallization from organic solvents under diverse conditions.
- Characterization using powder X-ray crystallography diffractometry (PXRD), differential scanning calorimetry (DSC), and thermogravimetric analysis (TG).
Main Results:
- Nine distinct polymorphic modifications of doxazosin mesylate were successfully obtained.
- Polymorphs Form 1 and Form 2 exhibited stability, with no observed transformations after 30 days at 20°C across 0%, 51%, and 99% relative humidity.
Conclusions:
- Multiple crystalline forms of doxazosin mesylate exist.
- The primary polymorphic forms of doxazosin mesylate demonstrate significant stability under a range of environmental humidity conditions, suggesting predictable solid-state behavior.